Free Cash Flow

The pediatric device firm posted 15% growth to $236.1M in 2025, issuing strong 2026 guidance fueled by its specialty bracing and European expansion.

Annexon is poised for a landmark year with potential first-in-class drugs for GBS and GA, promising to reset treatment standards and offer new hope.

BioXcel Therapeutics is pushing its drug IGALMI® for home use, a move that could transform mental healthcare but carries significant financial and safety risks.

FIS finalizes its $12B acquisition of Global Payments' issuer arm and sells its Worldpay stake, creating a new data-driven force in banking tech.

Utz Brands posted strong 2025 profit growth and market share gains, overcoming retail inventory issues caused by economic headwinds like SNAP delays.

EfTEN Real Estate Fund reports its best-ever operating results, proposing an 8% dividend hike, while a minor portfolio revaluation hints at market shifts.

Facing a Nasdaq delisting notice, social commerce firm Webuy Global has 45 days to devise a plan to fix its $2.1M stockholders' equity deficiency.

The Chinese auto-tech firm regained Nasdaq's minimum bid price but still faces delisting over its low market value, setting up a critical hearing.

EpicQuest Education's CES award highlights its AI university plans, but a closer look reveals a complex picture of innovation, market hype, and financial risk.

Koppers Holdings navigates a key leadership change as CFO Jimmi Sue Smith retires. Veteran Bradley Pearce takes the helm as interim financial chief.

The biotech firm now expects Phase 2 results in Q3 2026, accelerating hope for new CNS treatments and signaling strong operational momentum to investors.

Indonesia Energy Corp. starts pre-drilling for two new wells in Sumatra, a key move in its growth strategy and a boost for national energy security.

Upbound Group's new CEO and CFO head to the prestigious ICR Conference. Investors await insights on growth, credit trends, and financial inclusion strategy.

Ocugen heads to a top investor conference with a bold plan for its gene-agnostic therapy, aiming to treat blindness and secure its future in a crowded market.

As Valneva meets investors, all eyes are on its pivotal Lyme disease vaccine data, a potential game-changer for public health and the company's future.

Kyocera launches its Belharra industrial printer worldwide, offering a sustainable, high-quality inkjet alternative to traditional silver halide processes.

With a $200M facility, BlackOpal's GemStone uses blockchain to offer institutional investors high-yield Brazilian assets without the traditional credit risk.

As ENvue Medical prepares to ring the Nasdaq bell, a look at how its non-invasive tech for tube placement and pain relief is shaking up the MedTech world.

The investment giant's new podcast season tackles the energy trilemma, exploring AI's power thirst, the return of nuclear, and fossil fuel's role.

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.